NO20055368L - Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst - Google Patents

Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Info

Publication number
NO20055368L
NO20055368L NO20055368A NO20055368A NO20055368L NO 20055368 L NO20055368 L NO 20055368L NO 20055368 A NO20055368 A NO 20055368A NO 20055368 A NO20055368 A NO 20055368A NO 20055368 L NO20055368 L NO 20055368L
Authority
NO
Norway
Prior art keywords
phenyl
combinations
methylamide
piperazin
anxiety
Prior art date
Application number
NO20055368A
Other languages
English (en)
Norwegian (no)
Inventor
Mauro Corsi
Sergio Melotto
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20055368L publication Critical patent/NO20055368L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055368A 2003-04-17 2005-11-14 Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst NO20055368L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004122 WO2004091616A1 (fr) 2003-04-17 2004-04-16 Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete

Publications (1)

Publication Number Publication Date
NO20055368L true NO20055368L (no) 2005-11-14

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20055368A NO20055368L (no) 2003-04-17 2005-11-14 Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
NO20055367A NO20055367L (no) 2003-04-17 2005-11-14 Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20055367A NO20055367L (no) 2003-04-17 2005-11-14 Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Country Status (18)

Country Link
US (4) US20060241124A1 (fr)
EP (4) EP1653956A1 (fr)
JP (4) JP2006523650A (fr)
KR (2) KR20060003875A (fr)
CN (2) CN1809355A (fr)
AU (2) AU2004229181A1 (fr)
BR (2) BRPI0409377A (fr)
CA (2) CA2522313A1 (fr)
CO (1) CO5700753A2 (fr)
GB (1) GB0308968D0 (fr)
IS (2) IS8129A (fr)
MA (2) MA27731A1 (fr)
MX (2) MXPA05011064A (fr)
NO (2) NO20055368L (fr)
PL (2) PL377857A1 (fr)
RU (2) RU2005135647A (fr)
WO (4) WO2004091616A1 (fr)
ZA (2) ZA200508067B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (fr) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Forme dosifee stable d'un antidepresseur
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
WO2012175434A1 (fr) * 2011-06-20 2012-12-27 Glaxo Group Limited Formulations pharmaceutiques comprenant du vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
WO1998047514A1 (fr) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Utilisation d'un antagoniste du recepteur nk-1 et d'un inhibiteur selectif de reabsorption de la serotonine (ssri) dans le traitement de l'obesite
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
CN1434805A (zh) * 1999-12-17 2003-08-06 先灵公司 选择性神经激肽拮抗剂
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
CN100509782C (zh) * 2001-11-13 2009-07-08 先灵公司 Nk1拮抗剂
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2004229179A1 (en) 2004-10-28
IS8129A (is) 2005-11-15
EP1613325A1 (fr) 2006-01-11
ZA200508067B (en) 2007-02-28
MXPA05011064A (es) 2006-04-18
ZA200508068B (en) 2007-02-28
MA27731A1 (fr) 2006-01-02
MXPA05011063A (es) 2005-12-12
US20060241124A1 (en) 2006-10-26
JP2006523649A (ja) 2006-10-19
EP1615642A1 (fr) 2006-01-18
BRPI0409377A (pt) 2006-04-25
CN1809359A (zh) 2006-07-26
US20060217395A1 (en) 2006-09-28
AU2004229181A1 (en) 2004-10-28
WO2004091616A1 (fr) 2004-10-28
RU2005135649A (ru) 2006-03-20
IS8128A (is) 2005-11-15
CA2522311A1 (fr) 2004-10-28
EP1653956A1 (fr) 2006-05-10
CO5700753A2 (es) 2006-11-30
NO20055367L (no) 2005-11-14
US20060287325A1 (en) 2006-12-21
GB0308968D0 (en) 2003-05-28
KR20060003875A (ko) 2006-01-11
JP2006523652A (ja) 2006-10-19
RU2005135647A (ru) 2006-06-10
PL377857A1 (pl) 2006-02-20
JP2006523650A (ja) 2006-10-19
WO2004091617A1 (fr) 2004-10-28
MA27730A1 (fr) 2006-01-02
EP1615641A1 (fr) 2006-01-18
PL377858A1 (pl) 2006-02-20
WO2004091624A1 (fr) 2004-10-28
KR20060003876A (ko) 2006-01-11
WO2004091615A1 (fr) 2004-10-28
JP2006523651A (ja) 2006-10-19
CN1809355A (zh) 2006-07-26
CA2522313A1 (fr) 2004-10-28
US20060241143A1 (en) 2006-10-26
BRPI0409379A (pt) 2006-04-25

Similar Documents

Publication Publication Date Title
JP2005532372A5 (fr)
NO341591B1 (no) 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
UA100364C2 (xx) Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EP1453382A4 (fr) Methodes et compositions de correction des troubles de la conduction cardiaque
NO20065878L (no) Terapeutiske forbindelser
JP2008110984A5 (fr)
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL164645A (en) Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1h- benzidimazole-2-yl]-1- piperidinyl] ethyl]- alpha, alpha- dimethyl - benzenoacetic acid, method of preparing the same and use of the same in the preparation of medicaments
MXPA05011064A (es) Combinaciones de paroxetina y [1-(r)-(3, 5-bis-trifluorometi l-fenil)-etil] -metilamida del acido 4-(s)- (4-acetil-piperazin -1-il)-2- (r)-(4-fluoro -2-metil- fenil)-piperidin -1-carboxilico para tratamiento de depresion y/o ansiedad.
NO20091969L (no) N-(2-hydroksyetyl)-N-metyl-4-(quinolin-8-yl(1-(tiazol-4-ylmetyl)piperidin-4-yliden)metyl)benzamid, fremgangsmate for fremstilling av den sa vel som dens anvendelse for behandling av smerte, angst og depresjon
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
NO20081081L (no) Nytt salt II
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
TNSN05222A1 (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid
MX2023004626A (es) Moduladores de la via de respuesta integrada al estres.
MX2023004677A (es) Moduladores de la via de respuesta integrada al estres.
BRPI0516810A (pt) uso de conjugados de lipìdios no tratamento de doenças
CA2428511A1 (fr) Utilisations nouvelles d'agonistes 5-ht1a et d'inhibiteurs de recaptage de serotinine combines
WO2002053099A3 (fr) Methodes et compositions de traitement d'une parodontopathie
EE200100219A (et) (+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli estrid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application